T lymphocyte subsets and immunoglobulins in intracranial tumor patients before and after treatment, and based on histological type of tumors.
It has been reported that nervous system and peripheral immune system communicate with each other and the peripheral immune status is depressed in some intracranial tumor (ICT) patients pre operatively. Little is known about the immune status of intracranial tumor patients during the post operative survival period. We thus investigated total T cells (CD 11+), helper/inducer (CD4+) T cells, suppressor/cytotoxic (CD8+) T cells, B cells (CD19+) and serum immunoglobulins in peripheral blood in certain ICT patients before and after treatment, and based on the histological type of the tumors. Post treatment analysis were conducted 30 days after surgical removal of tumor tissue in benign brain tumor patients and 30 days after chemo therapy (CT)/radiotherapy (RT) following surgical removal of tumor tissue in malignant brain tumor patients. Decreased CD11+, CD4+ and increased CD8+ T cell counts were observed in both benign and malignant tumor cases before treatment compared with control subjects. After treatment, CD4+ T cell count increased and CD8+ T cell count decreased than their pre treatment levels. Serum IgA and IgG levels were decreased in both benign and malignant brain tumor patients before treatment than in control subjects. Serum IgM level has been increased in both benign and malignant tumor patients before and after treatment than in control subjects. Anaplastic malignant astrocytoma, medulloblastoma and glioblastoma multiforme patients showed higher IgM level than astrocytoma, meningioma and ependymoma patients. In conclusions, the depressed host cellular immunity in benign and malignant tumor patients before treatment may be due to the changes in CD4+ and CD8+ counts in addition to tumour specific immunosuppressive factors. Treatment procedures such as surgery, CT and RT may play certain role in the post operative depressed immunosuppression in malignant tumor patients. Humoral immune mechanism (CD19+) in the ICT patients was less markedly affected.
Kempuraj
D
D
Depaertment Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA 02111, USA. kempuraj@yahoo.com
Devi
R S
RS
Madhappan
B
B
Conti
P
P
Nazer
M Y
MY
Christodoulou
S
S
Reginald
J
J
Suthinthirarajan
N
N
Namasivayam
A
A
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001254:Astrocytoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology*; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D004806:Ependymoma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D006801:Humans; D007136:Immunoglobulins / Q000097:blood*; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008579:Meningioma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D009837:Oligodendroglioma / Q000188:drug therapy / Q000276:immunology / Q000473:pathology
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D007136:Immunoglobulins; D007166:Immunosuppressive Agents